Csenge Advisory Group Acquires 121,363 Shares of Axon Enterprise, Inc $AXON

Key Points

• Csenge Advisory Group increased its Axon stake by 10,535% in the third quarter, buying 121,363 shares to reach 122,515 shares, valued at about $51.8 million.
• Analysts maintain a consensus “Moderate Buy” rating, with a $612.18 average price target, though several firms recently lowered their targets.
• Axon’s latest quarter fell short of analyst expectations: earnings were $1.72 per share versus $1.89 expected, and revenue was $908.6 million versus $934.3 million expected.

Csenge Advisory Group raised its holdings in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 10,535.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 122,515 shares of the biotechnology company's stock after buying an additional 121,363 shares during the period. Axon Enterprise makes up approximately 2.0% of Csenge Advisory Group's portfolio, making the stock its 8th largest position. Csenge Advisory Group owned 0.15% of Axon Enterprise worth $51,765,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. State Street Corp raised its stake in shares of Axon Enterprise by 5,700.2% in the second quarter. State Street Corp now owns 213,561,844 shares of the biotechnology company's stock valued at $119,724,905,000 after acquiring an additional 209,879,882 shares in the last quarter. Envestnet Asset Management Inc. grew its stake in Axon Enterprise by 18,050.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 13,200,075 shares of the biotechnology company's stock worth $7,400,094,000 after purchasing an additional 13,127,348 shares in the last quarter. BlackRock Inc. grew its stake in Axon Enterprise by 4.3% during the 2nd quarter. BlackRock Inc. now owns 8,334,551 shares of the biotechnology company's stock worth $4,672,432,000 after purchasing an additional 345,365 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its stake in Axon Enterprise by 391,214.9% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 6,988,884 shares of the biotechnology company's stock worth $2,952,943,000 after purchasing an additional 6,987,098 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in Axon Enterprise by 5,022.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 4,266,589 shares of the biotechnology company's stock worth $1,802,719,000 after purchasing an additional 4,183,302 shares during the period. Institutional investors and hedge funds own 79.08% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on AXON shares. TD Cowen decreased their price objective on Axon Enterprise from $825.00 to $800.00 and set a "buy" rating for the company in a research note on Monday, October 26th. Royal Bank Of Canada cut their target price on shares of Axon Enterprise from $735.00 to $615.00 and set an "outperform" rating on the stock in a research note on Friday. Piper Sandler reaffirmed an "overweight" rating and issued a $540.00 target price (down from $561.00) on shares of Axon Enterprise in a report on Friday, November 6th. The Goldman Sachs Group decreased their price target on shares of Axon Enterprise from $715.00 to $675.00 and set a "buy" rating for the company in a research note on Monday, September 21st. Finally, Argus lifted their price target on shares of Axon Enterprise from $460.00 to $600.00 and gave the stock a "buy" rating in a research note on Thursday, September 3rd. Thirteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Axon Enterprise currently has an average rating of "Moderate Buy" and a consensus target price of $612.18.

Axon Enterprise Trading Down 0.2%

NASDAQ:AXON opened at $302.54 on Wednesday. The stock has a 50-day simple moving average of $430.30 and a 200-day simple moving average of $472.14. The stock has a market cap of $24.64 billion, a P/E ratio of 96.97, a P/E/G ratio of 5.76 and a beta of 1.48. Axon Enterprise, Inc has a 1 year low of $291.45 and a 1 year high of $665.07. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.60 and a current ratio of 3.00.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its earnings results on Thursday, November 5th. The biotechnology company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.89 by ($0.17). The business had revenue of $908.55 million for the quarter, compared to analyst estimates of $934.33 million. Axon Enterprise had a return on equity of 3.87% and a net margin of 7.56%. Axon Enterprise's revenue was up 27.8% on a year-over-year basis. During the same period last year, the business posted $1.17 EPS. As a group, analysts anticipate that Axon Enterprise, Inc will post 2.10 earnings per share for the current fiscal year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, insider Isaiah Fields sold 1,017 shares of the firm's stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $480.45, for a total transaction of $488,617.65. Following the sale, the insider owned 56,264 shares of the company's stock, valued at approximately $27,032,038.80. This trade represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Joshua Isner sold 16,775 shares of the business's stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $574.43, for a total transaction of $9,636,063.25. Following the sale, the president owned 296,974 shares of the company's stock, valued at $170,590,774.82. This represents a 5.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 37,397 shares of company stock valued at $21,234,034. Company insiders own 4.20% of the company's stock.

Key Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon is investing $1.2 billion for a 37% stake in drone maker Skydio and will become its U.S. public-safety distributor. The deal could broaden Axon’s public-safety technology offering, though its scale also brings investment and execution risks. Axon invests in Skydio
• Positive Sentiment: West Fargo police plan to replace Flock technology with Axon’s system, including new AI features—an example of continued adoption by public-safety customers. West Fargo police adoption
• Positive Sentiment: Despite lowering its price target, Barclays retained an “overweight” rating at $507; Northland reportedly still sees a $540 target after the stock’s steep fall from its August high. These views suggest some analysts see substantial recovery potential, though targets are not guarantees. Northland target outlook
• Neutral Sentiment: A short-interest report lists 0 shares short, despite describing a large increase. The figure appears inconsistent and does not provide a reliable indication of short-selling pressure.
• Negative Sentiment: Axon’s third-quarter adjusted EPS of $1.72 and revenue of about $909 million fell short of estimates. Cautious guidance and roughly $130 million in federal-contract revenue shifting out of 2026 have weighed on the outlook; shares have fallen sharply since the results, while Motorola rose after its earnings beat. Axon versus Motorola after earnings
• Negative Sentiment: Law firms announced investigations into potential securities-law violations. These are allegations under investigation, not findings of wrongdoing, but may add legal and reputational uncertainty for investors. Axon securities investigation notice

Axon Enterprise Profile

Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals. The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.